Effect of Preoperative Recombinant Human Erythropoietin on Transfusion Risk in Valvular Heart Surgery

Yonsei University

Status: Completed

Conditions: Cardiac Surgery

Treatments: Drug: rhEPO

Study type: Interventional

Funder types: Other

Identifiers

NCT00939978

4-2008-0427

Details and patient eligibility

About

The administration of rhEPO on the one day before cardiac surgery will be effective to decrease the bleeding due to the surgery.

Enrollment: 74 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• The 90 patients who are planned to have the heart surgery during this study period.(minimum age 20)

Exclusion criteria

• Uncontrolled hypertension(diastolic blood pressure(DBP)>100 mmHg), Hct > 45%, Plt. count)>450,000
• There are no history of seizure, thrombus, cancer, acute hepatitis, alcoholism, peripheral blood vessel disease, pure red blood cell dysfunction, liver function failure, chronic multiple arthritis.
• No pregnancy, acute hyper parathyroidism.

Trial design

74 participants in 2 patient groups, including a placebo group

Venoferrum

Active Comparator group

Treatment:

Drug: rhEPO

saline

Placebo Comparator group

Treatment:

Drug: rhEPO